ANAB ANAPTYSBIO, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1370053 · Fiscal year ends 06/30
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY107.7%
TTM net income YoY81.0%
TTM EPS YoY78.1%
Revenue 3-yr CAGR179.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin35.9%
Net margin-11.5%
FCF margin1.9%
EBITDA margin36.0%
Returns
ROE-114.6%
ROA-7.1%
ROIC (approx.)—
Asset turnover0.62x
Leverage & solvency
Liabilities / assets96.1%
Debt / equity0.00x
Current ratio7.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.17x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $234.60M | $91.28M |
| R&D expense | $135.97M | $163.84M |
| SG&A expense | $11.35M | $13.63M |
| Operating income | $226.90M | $66.15M |
| Pretax income | $162.28M | $31.14M |
| Income tax | $772,000 | $158,000 |
| Net income | -$13.23M | -$145.23M |
| EBITDA | $226.92M | $66.17M |
| EPS (basic) | -0.46 | -5.12 |
| EPS (diluted) | -0.44 | -4.92 |
| Weighted avg. shares (diluted) | 30.23M | 29.54M |
| Balance sheet | ||
| Cash & equivalents | $138.20M | $23.08M |
| Short-term investments | $73.44M | $262.29M |
| Receivables | $33.85M | $40.77M |
| Current assets | $350.25M | $431.88M |
| PP&E, net | $111,000 | $131,000 |
| Total assets | $364.39M | $483.83M |
| Current liabilities | $38.62M | $45.43M |
| Total liabilities | $327.19M | $412.97M |
| Shareholders' equity | $37.21M | $70.87M |
| Shares outstanding | 28.02M | 30.47M |
| Cash flow statement | ||
| Operating cash flow | $19.70M | -$135.34M |
| Capital expenditure | $87,000 | $358,000 |
| Free cash flow | $19.61M | -$135.69M |
| Investing cash flow | $228.03M | $31.36M |
| Financing cash flow | -$132.61M | $127.05M |
| Depreciation & amortization | $20,000 | $20,000 |
| Stock-based compensation | $3.77M | $7.22M |
| Share buybacks | $68.63M | $456,000 |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.